DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Phase 2

Completed

Conditions: Advanced Cancers

Interventions: Drug: LY2606368

First Posted Date: 2016-08-22

Last Posted Date: 2022-10-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT02873975

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Palbociclib With Everolimus + Exemestane In BC

Phase 1

Completed

Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Hormone Receptor (HR)-Positive Breast Cancer

Interventions: Drug: Palbociclib
Drug: Everolimus
Drug: Exemestane

First Posted Date: 2016-08-18

Last Posted Date: 2022-08-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 41

Registration Number: NCT02871791

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

Phase 2

Active, not recruiting

Conditions: Graft vs. Host Disease

Interventions: Drug: Placebo
Drug: Obinutuzumab

First Posted Date: 2016-08-15

Last Posted Date: 2024-04-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 181

Registration Number: NCT02867384

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

Phase 2

Completed

Conditions: Peritoneal Cancer
Ovarian Cancer
Fallopian Tube Cancer

Interventions: Drug: Pembrolizumab
Drug: Pegylated Liposomal Doxorubicin (PLD)

First Posted Date: 2016-08-12

Last Posted Date: 2022-09-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 26

Registration Number: NCT02865811

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Northwell Hospital Monter Cancer Center, Lake Success, New York, United States

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer

Phase 1

Completed

Conditions: Cancer of Head and Neck
Cancer of Cervix
Cancer of Anus

Interventions: Drug: DPX-E7 vaccine
Drug: Cyclophosphamide

First Posted Date: 2016-08-12

Last Posted Date: 2024-01-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 11

Registration Number: NCT02865135

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies

Not Applicable

Recruiting

Conditions: Liver Cancer

Interventions: Device: Traditional Delivery
Device: TriNav
Drug: Doxorubicin

First Posted Date: 2016-08-03

Last Posted Date: 2024-01-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT02853500

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Phase 1

Active, not recruiting

Conditions: Brain Cancer

Interventions: Drug: MK-3475

First Posted Date: 2016-08-02

Last Posted Date: 2024-11-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT02852655

Locations: 🇺🇸
UT, MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

and more 4 locations

Qigong For PPSP In Breast Cancer Pain In Breast Cancer Survivors

Not Applicable

Completed

Conditions: Stage 0-III Breast Cancer
Breast Cancer Surgery Pain
Breast Cancer

Interventions: Other: Qigong Mind-Body Exercise

First Posted Date: 2016-07-29

Last Posted Date: 2023-02-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT02848989

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Implementation of a System-level Tobacco Treatment Intervention

Not Applicable

Active, not recruiting

Conditions: Lung Cancer
Smoking Cessation

Interventions: Other: CEASE
Other: Usual Care Tobacco Treatment Services

First Posted Date: 2016-06-28

Last Posted Date: 2024-05-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 263

Registration Number: NCT02816697

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Phase 2

Active, not recruiting

Conditions: Carcinoid Tumors

Interventions: Drug: Ramucirumab
Drug: Somatostatin Analog

First Posted Date: 2016-06-10

Last Posted Date: 2024-03-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 43

Registration Number: NCT02795858

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy